Early Postnatal Oxytocin Restores Hippocampal Plasticity in Fragile X Mice

Fragile X syndrome remains a leading genetic cause of inherited intellectual disability and autism spectrum disorder, yet clinical management is largely limited to treating associated symptoms like irritability and anxiety [1, 2, 3]. While oxytocin has demonstrated efficacy in improving social-emotional recognition in some clinical trials, its impact on the debilitating cognitive impairments of the disorder remains poorly defined [4, 5, 6]. Clinicians currently face a lack of validated biomarkers and disease-modifying therapies that can address the core neurodevelopmental disruptions in synaptic communication [7, 8, 9]. Recent research into the timing of pharmacological interventions suggests that the therapeutic window for modulating brain development may be narrower than previously thought [7, 10]. To address this gap, researchers investigated whether early-life oxytocin treatment can provide lasting restoration of memory function and hippocampal plasticity into adulthood, potentially offering a targeted strategy for cognitive rescue.